EVIDENCE LIBRARY
Methamphetamine-Associated Psychosis Case Remained Agitated Despite Lorazepam and Multiple Antipsychotics
A severe psychotic-relapse case describes limited apparent response to extensive medication. Later recovery cannot establish that one particular drug caused improvement.
A severe psychotic-relapse case describes limited apparent response to extensive medication. Later recovery cannot establish that one particular drug caused improvement.
The clinical problem
A thirty-year-old man with schizoaffective disorder developed extreme agitation and paranoia after cannabis and crystal-methamphetamine use. Existing depot treatment was supplemented with several antipsychotics and lorazepam.
The report describes persistent dangerous behavior despite treatment, followed by recovery roughly four to five days after presentation. Pharmacogenetic testing did not identify the proposed explanation for poor antipsychotic response.
Observed resistance is not a controlled experiment
Many medicines were administered during an evolving intoxication. The authors interpreted the course as largely self-limited, but the case cannot quantify the benefit or lack of benefit of each sedative.
An unrevealing pharmacogenetic test does not exclude every metabolic, pharmacodynamic, or behavioral explanation. Nor can administered doses alone establish an exact remaining body burden of methamphetamine.
Forensic reading
Distinguish control of dangerous behavior, treatment of psychosis, consciousness level, and adverse-event monitoring. This report does not supply a universally appropriate lorazepam escalation strategy or prove that high-dose combinations are safe. It illustrates the uncertainty of attributing response when severe intoxication and multiple interventions evolve together.
Source paper
Original analysis of the supplied journal article, identified as PMC5011982.